• Dr Richard Mead
    Dr Richard Mead PhD

    Richard Mead is a Senior Lecturer (associate professor) at the Sheffield Institute for Translational Neuroscience. He has 16 years’ experience in preclinical drug discovery in academia and industry and has a track record of taking compounds through preclinical programs to nomination for clinical development. He has worked on the target pathway (NRF2-KEAP1) for over 8 years and taken a reactive Nrf2 activator from screening to orphan designation with the EMA for MND. He is a named inventor on 4 patents and has attracted funding of £7.4M as primary investigator and co-investigator.

  • Dame Professor Pamela Shaw
    Dame Professor Pamela Shaw DBE MBBS MD FRCP FMedSci FAAN FANA FAAAS

    Pamela Shaw is the Vice President and Head of the Faculty of Medicine and Dentistry, University of Sheffield and Director of the Sheffield Institute for Translational Neuroscience (SITraN). She is also Director of the NIHR Biomedical Research Centre Translational Neuroscience for Chronic Neurological Disorders. Professor Shaw is a clinician scientist and world leading expert on mechanisms and treatment of motor neuron disease. She has published over 425 papers and has an H Index of 88.